Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.e

Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

Publications

Ishikawa Y, Yukawa N, Kawabata D, Ohmura K, Fujii T, Usui T, Mimori T

A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept.

Clinical rheumatology 2011 Mar;30;429-32 — 2011 Mar — 429-32

Wetter DA, Davis MD

Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.

Mayo Clinic proceedings 2009 Nov;84;979-84 — 2009 Nov — 979-84

Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA

Autoimmune diseases induced by TNF-targeted therapies.

Best practice & research. Clinical rheumatology 2008 Oct;22;847-61 — 2008 Oct — 847-61

Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA

Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Medicine 2007 Jul;86;242-51 — 2007 Jul — 242-51